1-[2-[4-(2,4-Difluorophenoxy)Piperidin-1-Yl]-3-[[(3R)-Oxolan-3-Yl]Amino]-7,8-Dihydro-5H-Pyrido[3,4-B]Pyrazin-6-Yl]Ethanone

1 trials

Filter these 1 trials by condition, phase, country and more.

Open in Search →

1 Registered trials

0 Recruiting

1 Completed trials

1 Sponsors

5 Countries

Phase II

Phase II: 1

Indications tested

Parkinson's disease 1

Sponsors using this IMP

Cerevance Beta Inc. 1

All trials

1 total

Phase 2 Study of CVN424 Ended

2024-516811-25-00 Phase II 5 countries Cerevance Beta Inc.

Showing 1–1 of 1 trials

← All drugs A–Z